NEW YORK (GenomeWeb) – Antibody firm Abcam has developed a new next-generation sequencing-based workflow that it said could allow it to produce reagents to a variety of difficult to target proteins.

The method uses NGS to more thoroughly explore the antibody repertoire produced by rabbits than is possible in conventional rabbit hybridoma workflows, allowing the company to isolate and analyze molecules in what John Baker, Abcam's vice president, diagnostics and licensing, termed "the long tail of the immune response."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.